Wednesday, September 23, 2020

Synthetic Biologics Inc. [SYN] moved down -0.47: Why It’s Important

Must read

SunCoke Energy Inc. [SXC] moved up 10.80: Why It’s Important

SunCoke Energy Inc. gained 10.80% on the last trading session, reaching $4.00 price per share at the time. SunCoke Energy Inc. represents 82.80...

The Travelers Companies Inc. [TRV] Revenue clocked in at $31.41 billion, down -18.11% YTD: What’s Next?

The Travelers Companies Inc. stock went on a downward path that fall over -2.02% on Tuesday, amounting to a one-week price decrease of...

Sumo Logic Inc. [SUMO] Revenue clocked in at $181.40 million, down -7.18% YTD: What’s Next?

Sumo Logic Inc. gained 5.54% or 1.31 points to close at $24.95 with a heavy trading volume of 2117000 shares. If we look...

JPMorgan Chase & Co. [JPM] fell -31.63% so far this year. What now?

JPMorgan Chase & Co. slipped around -3.04 points on Monday, while shares priced at $95.31 at the close of the session, down -3.09%....

Synthetic Biologics Inc. [AMEX: SYN] plunged by $0.0 during the normal trading session on Tuesday and reaching a high of $0.68 during the day while it closed the day at $0.64. The company report on June 30, 2020 that Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase.

— Initial Indication Will Seek to Reduce Acute Intestinal Side Effects Associated with Radiation Therapy in Cancer Patients –.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (“GI”) diseases in areas of high unmet need, today announced that it submitted an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its SYN-020 Intestinal Alkaline Phosphatase (“IAP”) program. The IND application supports an initial indication of SYN-020 for the treatment of radiation enteropathy secondary to pelvic cancer therapy. Under the IND application, the Company intends to conduct a Phase 1 single ascending dose study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters.

Synthetic Biologics Inc. stock has also gained 11.71% of its value over the past 7 days. However, SYN stock has inclined by 55.00% in the 3 months of the year. Over the past six months meanwhile, it has gained 48.62% and gained 25.37% year-on date.

The market cap for SYN stock reached $11.86 million, with 19.44 million shares outstanding and 19.30 million shares in the current float. Compared to the average trading volume of 621.99K shares, SYN reached a trading volume of 3637755 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Synthetic Biologics Inc. [SYN]:

FBR & Co. have made an estimate for Synthetic Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 06, 2017. While these analysts kept the previous recommendation, FBR Capital raised their target price from $10 to $9. The new note on the price target was released on May 06, 2016, representing the official price target for Synthetic Biologics Inc. stock. Previously, the target price had yet another raise to $10, while FBR Capital analysts kept a Outperform rating on SYN stock.

The Average True Range (ATR) for Synthetic Biologics Inc. is set at 0.06

SYN stock trade performance evaluation

Synthetic Biologics Inc. [SYN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.71. With this latest performance, SYN shares gained by 11.49% in over the last four-week period, additionally plugging by 48.62% over the last 6 months – not to mention a rise of 35.24% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYN stock in for the last two-week period is set at 61.06, with the RSI for the last a single of trading hit 65.05, and the three-weeks RSI is set at 59.07 for Synthetic Biologics Inc. [SYN]. The present Moving Average for the last 50 days of trading for this stock 0.5466, while it was recorded at 0.6031 for the last single week of trading, and 0.4496 for the last 200 days.

Synthetic Biologics Inc. [SYN]: An insightful look at the core fundamentals

Return on Total Capital for SYN is now -81.02, given the latest momentum, and Return on Invested Capital for the company is -69.24. Return on Equity for this stock declined to -69.99, with Return on Assets sitting at -64.60. When it comes to the capital structure of this company, Synthetic Biologics Inc. [SYN] has a Total Debt to Total Equity ratio set at 5.03. Additionally, SYN Total Debt to Total Capital is recorded at 4.79, with Total Debt to Total Assets ending up at 4.19.

Reflecting on the efficiency of the workforce at the company, Synthetic Biologics Inc. [SYN] managed to generate an average of -$1,391,182 per employee.Synthetic Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.60.

Earnings per share (EPS) analysis for Synthetic Biologics Inc. [SYN] stock

With the latest financial reports released by the company, Synthetic Biologics Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -30.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYN.

Synthetic Biologics Inc. [SYN]: Insider Ownership positions

There are presently around $1 million, or 7.40% of SYN stock, in the hands of institutional investors. The top three institutional holders of SYN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 889,619, which is approximately 29.17% of the company’s market cap and around 0.13% of the total institutional ownership; BRIDGEWAY CAPITAL MANAGEMENT INC, holding 109,300 shares of the stock with an approximate value of $69000.0 in SYN stocks shares; and ACADIAN ASSET MANAGEMENT LLC, currently with $39000.0 in SYN stock with ownership of nearly New of the company’s market capitalization.

Positions in Synthetic Biologics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in Synthetic Biologics Inc. [AMEX:SYN] by around 458,642 shares. Additionally, 8 investors decreased positions by around 411,048 shares, while 13 investors held positions by with 513,384 shares. The mentioned changes placed institutional holdings at 1,383,074 shares, according to the latest SEC report filing. SYN stock had 8 new institutional investments in for a total of 251,360 shares, while 3 institutional investors sold positions of 325,641 shares during the same period.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Splunk Inc. [SPLK] is 23.48% higher this YTD. Is it still time to buy?

Splunk Inc. price surged by 4.05 percent to reach at $7.2. A sum of 1823847 shares traded at recent session while its average...

For Workday Inc. [WDAY], Wells Fargo sees a rise to $240. What next?

Workday Inc. gained 4.05% or 8.25 points to close at $211.80 with a heavy trading volume of 1831577 shares. It opened the trading...

Market Analysts see YETI Holdings Inc. [YETI] gaining to $48. Time to buy?

YETI Holdings Inc. closed the trading session at $47.04 on 09/22/20. The day’s price range saw the stock hit a low of $44.565,...

Viveve Medical Inc. [VIVE] Revenue clocked in at $4.50 million, down -55.36% YTD: What’s Next?

Viveve Medical Inc. jumped around 0.02 points on Tuesday, while shares priced at $0.56 at the close of the session, up 4.22%. Viveve...

Sunrun Inc. [RUN] Is Currently 4.32 below its 200 Period Moving Avg: What Dose This Mean?

Sunrun Inc. stock went on an upward path that rose over 4.32% on Tuesday, amounting to a one-week price increase of more than...